Skip Ribbon Commands
Skip to main content
Sign In
Navigate Up

26363 Invitae Breast and Gyn Cancers Panel (01201)

Invitae Breast and Gyn Cancers Panel (01201)
Test Code: BRGYNSO
Specimen Requirements
Fasting RequiredSpecimen TypePreferred Container/TubeAcceptable Container/TubeSpecimen VolumeSpecimen Minimum Volume
(allows for 1 repeat)		Pediatric Minimum Volume
(no repeat)
​No​Whole Blood​EDTA Lavender Top Tube (LTT)​​3 mL​​1.5 mL
Acceptable Specimen Types

​Alternate Specimens:  Saliva, assisted saliva, buccal swab and gDNA

Specimen Stability Information
Specimen TypeTemperatureTime
​ ​Whole Blood​Ambient​48 hours
​Refrigerated​14 days
Rejection Criteria
Hemolyzed, clotted, or frozen blood
​Blood from patients who have had an allogeneic (non-self donor) bone marrow transplant​​
​Blood from patients who have had an allogeneic (non-self donor) stem cell transplant​​
Blood from patients who had a blood transfusion less than two weeks prior to specimen collection​​
Performing Laboratory Information
Performing LocationDay(s) Test PerformedAnalytical TimeMethodology/Instrumentation
​Invitae​Monday through Saturday​10-21 days​Next Generation Sequencing Deletion/Duplication Analysis
Reference Lab
Invitae
Test Information

​The Invitae Breast and Gyn Cancers Panel analyzes genes that are associated with hereditary predisposition breast, ovarian, and endometrial/uterine cancers. The genetic heterogeneity associated with these conditions can make it difficult to use phenotype as the sole criterion to select a definitive cause. These genes were curated based on the available evidence to date in order to provide analysis for hereditary breast and gynecologic cancers. Given the clinical overlap of hereditary susceptibility to breast and gynecologic cancers, broad panel testing allows for an efficient evaluation of several potential genes based on a single clinical indication. Some genes in this test may also be associated with additional unrelated disorders, which are not included in the list of disorders tested. Genetic testing of these genes may help confirm a clinical diagnosis, help predict disease prognosis and progression, facilitate early detection of symptoms, inform family planning and genetic counseling, or promote enrollment in clinical trials.

Reference Range Information

An interpretive report will be provided

Interpretation

​An interpretive report will be provided

Outreach CPTs
CPTModifier
(if needed)		QuantityDescriptionComments
81162​​​1​BRCA1, BRCA2 gene analysis; full sequence analysis and full duplication/deletion analysis​If appropriate
​81432​​1​Hereditary breast cancer-related disorders; genomic sequence analysis panel, must include sequencing of at least 10 genes, always including BRCA1, BRCA2, CDH1, MLH1, MSH2, MSH6, PALB2, PTEN, STK11, and TP53.​If appropriate
​81433​​1​Duplication/deletion analysis panel, must include analysis for BRCA1, BRCA2, MLH1, MSH2, and STK11.​If appropriate
Ordering Applications
Ordering ApplicationDescription
​COM​Invitae Breast and GYN Cancer Panel (#1201)
​Cerner​Invitae Breast and GYN Cancer Panel (#1201)
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Fasting RequiredSpecimen TypePreferred Container/TubeAcceptable Container/TubeSpecimen VolumeSpecimen Minimum Volume
(allows for 1 repeat)		Pediatric Minimum Volume
(no repeat)
​No​Whole Blood​EDTA Lavender Top Tube (LTT)​​3 mL​​1.5 mL
Acceptable Specimen Types

​Alternate Specimens:  Saliva, assisted saliva, buccal swab and gDNA

Specimen Stability Information
Specimen TypeTemperatureTime
​ ​Whole Blood​Ambient​48 hours
​Refrigerated​14 days
Rejection Criteria
Hemolyzed, clotted, or frozen blood
​Blood from patients who have had an allogeneic (non-self donor) bone marrow transplant​​
​Blood from patients who have had an allogeneic (non-self donor) stem cell transplant​​
Blood from patients who had a blood transfusion less than two weeks prior to specimen collection​​
Reference Range Information

An interpretive report will be provided

Interpretation

​An interpretive report will be provided

For more information visit:
Performing Laboratory Information
Performing LocationDay(s) Test PerformedAnalytical TimeMethodology/Instrumentation
​Invitae​Monday through Saturday​10-21 days​Next Generation Sequencing Deletion/Duplication Analysis
Reference Lab
Invitae
For billing questions, see Contacts
Outreach CPTs
CPTModifier
(if needed)		QuantityDescriptionComments
81162​​​1​BRCA1, BRCA2 gene analysis; full sequence analysis and full duplication/deletion analysis​If appropriate
​81432​​1​Hereditary breast cancer-related disorders; genomic sequence analysis panel, must include sequencing of at least 10 genes, always including BRCA1, BRCA2, CDH1, MLH1, MSH2, MSH6, PALB2, PTEN, STK11, and TP53.​If appropriate
​81433​​1​Duplication/deletion analysis panel, must include analysis for BRCA1, BRCA2, MLH1, MSH2, and STK11.​If appropriate
For most current information refer to the Marshfield Laboratory online reference manual.